3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
21
Neoplasms
6
Neoplasm Metastasis
5
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Triple Negative Breast Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hereditary Sensory and Autonomic Neuropathies
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
Breast Diseases
2
von Hippel-Lindau Disease
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors Refractory to Standard Therapy
1
Solid Tumor, Adult
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Rare Tumor
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasm, Residual
1
Melanoma
1
Medulloblastoma
1
Malignant Female Reproductive System Neoplasm
1
Lung Neoplasms
1
Interventions
Cyclophosphamide
7
venetoclax
6
Azacitidine
6
fludarabine
5
Cytarabine
4
Blood Specimen Collection
4
daratumumab
3
Lenalidomide
3
Daunorubicin
3
tislelizumab
2
fludarabine phosphate
2
blinatumomab
2
Rituximab
2
Liquid Biopsy
2
Idarubicin
2
Gemtuzumab
2
Capecitabine
2
Busulfan
2
trastuzumab deruxtecan
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sugemalimab
1
sacituzumab govitecan
1
relugolix
1
pembrolizumab
1
pegaspargase
1
palbociclib
1
obinutuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm, Residual
×
palbociclib
×
Clear all
NCT04841148
2026-04-09
PALAVY
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
96 enrolled